Larry Kocot Joins Emerging Therapy Solutions Board of Directors 

 // News

March 7  

 ETS is pleased to welcome healthcare industry expert Larry Kocot to its Board of Directors. 

March 7, 2024 – Bloomington, MN – Emerging Therapy Solutions® (ETS), today announced the appointment of S. Lawrence (Larry) Kocot, to its Board of Directors. 

Larry Kocot is a respected business strategist and healthcare industry expert and has been working in the healthcare industry for over three decades. 

“We are very pleased to have Larry join the ETS Board” said, Matthew Mackowski, Chairman of the Board of Directors of ETS. “Larry has served in important senior roles at the nexus of law, policy and business in healthcare and life sciences and he will add a wealth of knowledge and expertise to our board.” 

Kocot recently retired from KPMG LLP, where he was a Principal in the Advisory practice and National Leader of the Center for Healthcare Regulatory Insight. 

Prior to KPMG, Kocot was a Visiting Fellow of the Economic Studies Program at the Brookings Institution, and Senior Counsel at Epstein Becker Green, PC. Larry served as Senior Advisor to the Administrator at the Centers for Medicare & Medicaid Services (CMS) at the Department of Health and Human Services for the implementation of Medicare Part D, where he was a key member of the management and operations team. Prior to his government service, Larry was Senior Vice President and General Counsel at the National Association of Chain Drug Stores. 

Kocot is currently a principal at Kocot & Associates, LLC. In addition to the ETS board, Larry currently serves as Board Director of WPS Health Solutions and is a member of the Commonwealth of Virginia Board of Pharmacy. 

About Emerging Therapy Solutions Emerging Therapy Solutions (ETS) helps reinsurance and stop-loss payers, health plans and self-funded employers manage risk associated with high-cost therapies for rare and complex conditions. ETS offers a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies. Learn more at 


Success message!
Warning message!
Error message!